At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
Quetiapine fumarate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)·interventional·Posted Jul 10, 2007·Updated Mar 19, 2019
In Brief
A Phase 2 clinical trial evaluating Quetiapine fumarate and Placebo for Alcoholism and Alcohol Abuse. Completed, enrolled 224 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism, Alcohol Abuse
CountriesUnited States
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartDec 2007
Primary CompletionAug 2009
Study CompletionMar 2010
TodayJul 2026
First PostedJul 10, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.0 years ago
Interventions
Quetiapine fumaratedrug
Quetiapine fumarate- taken daily, for 12 weeks
Placeboother
Placebo